CA-HAI-ROBOTICS
Hai Robotics, a leading provider of intelligent automated warehousing solutions, has won the MHI Innovation Award for Best Innovation of an Existing Product for their A42T Autonomous Case-handling Robot (ACR). This prestigious award was announced at ProMat 2023, held in Chicago, on Wednesday, March 22nd.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230327005769/en/
The MHI Innovation Award recognizes Hai Robotics for their groundbreaking work in developing advanced equipment for automated storage and retrieval solutions (ASRS) and recognizes the company's commitment to advancing their customer’s success with innovative and cutting-edge technology.
The A42T ACR is the first goods-to-person equipment that extends upward allowing facilities to store items up to 10m (32+ feet) high, while remaining independent of any storage medium. It is highly intelligent, able to handle most totes or container sizes and types, even cardboard boxes, on standard industry shelving structures. Comparable systems often require unique and expensive custom precision structures with limited tote options to function, but the A42T ACR is a revolutionary robotic design, freeing facilities of the old rigid ASRS constructs. This robot provides maximum system flexibility typically seen with AMR or AGV technology while allowing facilities to obtain modern warehouse density with maximum use of vertical storage.
This award is a testament to Hai Robotics’ dedication to excellence and its ability to deliver intelligent automation solutions that help businesses increase efficiency, reduce costs, reduce storage footprint, and improve overall productivity.
"We are thrilled to have won the Innovation Award at ProMat 2023," said Brian Zheng, CEO of Hai Robotics USA. "This award is a recognition of our team's hard work, dedication, and commitment to driving innovation in the industry. We are proud to be at the forefront of intelligent warehouse automation and are committed to delivering advanced solutions that help our customers stay ahead of the game."
The ProMat 2023 event brought together many thousands of industry experts, professionals, and businesses from around the world to showcase the latest technologies, products, and solutions in the field of automation and material handling. The event is an excellent opportunity for attendees to explore new technologies. Visitors were able to witness the A42T ACR live where it demonstrated 32-foot-high tote picks from one of the tallest structures built at the event.
"We are honored to have received this prestigious award, and we thank MHI for hosting such an exceptional event," said Rebecca Lennartz, Director of Marketing for Hai Robotics USA. "We look forward to continuing to drive innovation in the industry and helping businesses achieve their automation goals."
About HAI Robotics
Hai Robotics is a leading global provider of intelligent automated storage and retrieval systems (ASRS). Their ASRS solutions provide modern storage density, reducing their customer’s storage footprints up to 75%, increasing workflow efficiency gains up to 4x, maximizing order pick accuracy to 99.9+%, and improving daily orders fulfilled rate over 170%.
Their Autonomous Case-handling Robots (ACR) are the key equipment in their systems. These robots maximize the use of vertical space, managing the storage of goods 32+ feet high. Their solutions are independent of any storage medium so the ASRS can be built using almost any standard racking structure, and the equipment manages most kinds and sizes of bins, trays, cardboard cartons, and a variety of containers and materials.
Hai Robotics provides intelligent ASRS solutions made for real world applications.
To know more about Hai Robotics and their A42T ACR, visit their website at https://www.hairobotics.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230327005769/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom